Aquestive Therapeutics (AQST) Change in Accured Expenses (2017 - 2026)

Aquestive Therapeutics' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$2.8 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 0.97% year-over-year to -$2.8 million; the TTM figure through Mar 2026 stood at $3.0 million (up 225.47% YoY), while the FY2025 annual figure was $3.0 million, up 303.22% from the prior year.
• Change in Accured Expenses was -$2.8 million for Q1 2026 at Aquestive Therapeutics, down from $5.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.1 million in Q4 2025 to a low of -$4.0 million in Q1 2022.
• Historically, Change in Accured Expenses has averaged -$362352.9 across 5 years, with a median of -$25000.0 in 2022.
• Biggest YoY gain for Change in Accured Expenses was 3916.0% in 2023; the steepest drop was 160.3% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at -$25000.0 in 2022, then soared by 3916.0% to $954000.0 in 2023, then declined by 3.98% to $916000.0 in 2024, then soared by 455.68% to $5.1 million in 2025, then sank by 155.07% to -$2.8 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.8 million (Q1 2026), $5.1 million (Q4 2025), and $118000.0 (Q3 2025), per Business Quant data.